13 Healthcare Stocks Moving In Tuesday's Pre-Market Session


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Gainers

  • RTI Surgical Hldgs, Inc. (NASDAQ:RTIX) stock surged 92.0% to $5.30 during Tuesday's pre-market session.
  • Adaptimmune Therapeutics, Inc. (NASDAQ:ADAP) shares surged 33.1% to $5.31.
  • La Jolla Pharmaceutical, Inc. (NASDAQ:LJPC) shares rose 12.3% to $7.86. According to the most recent rating by H.C. Wainwright, on November 26, the current rating is at Neutral.
  • Acasti Pharma, Inc. (NASDAQ:ACST) stock increased by 5.4% to $0.80. The most recent rating by B. Riley FBR, on January 13, is at Neutral, with a price target of $2.00.
  • Aurora Cannabis, Inc. (NYSE:ACB) shares increased by 3.8% to $1.76. The most recent rating by Piper Sandler, on January 10, is at Underweight, with a price target of $1.00.
  • NantKwest, Inc. (NASDAQ:NK) shares rose 2.9% to $7.00.
  • Aphria, Inc. (NYSE:APHA) shares surged 2.8% to $5.57. According to the most recent rating by B of A Securities, on January 13, the current rating is at Neutral.
  • Canopy Growth, Inc. (NYSE:CGC) shares rose 2.3% to $23.65. According to the most recent rating by Bank of America, on November 20, the current rating is at Buy.
  • Cronos Group, Inc. (NASDAQ:CRON) stock increased by 2.3% to $7.68. The most recent rating by Bank of America, on November 13, is at Buy, with a price target of $15.00.
  • Tilray, Inc. (NASDAQ:TLRY) stock increased by 1.7% to $17.66. The most recent rating by B of A Securities, on January 13, is at Neutral, with a price target of $18.00.

 

Losers

  • Dare Bioscience, Inc. (NASDAQ:DARE) stock decreased by 9.7% to $1.49 during Tuesday's pre-market session.
  • AbbVie, Inc. (NYSE:ABBV) shares plummeted 1.1% to $87.55. The most recent rating by Cowen & Co., on December 26, is at Outperform, with a price target of $98.00.
  • Genmab, Inc. (NASDAQ:GMAB) shares plummeted 1.1% to $22.41. The most recent rating by SunTrust Robinson Humphrey, on January 13, is at Buy, with a price target of $28.00.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsMovers & ShakersPre-Market OutlookMarketsMoversTrading IdeasGeneralBiotechnologyHealth CareHealthcare Stocks Pre-Market MoversTop Gainers